Shree Ganesh Remedies Ltd is Rated Strong Sell

Understanding the Current Rating

The Strong Sell rating assigned to Shree Ganesh Remedies Ltd indicates a cautious stance for investors, suggesting that the stock is expected to underperform relative to the broader market. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the company’s investment appeal and risk profile.

Quality Assessment

As of 15 February 2026, Shree Ganesh Remedies Ltd holds an average quality grade. This reflects moderate operational efficiency and business fundamentals. While the company has demonstrated some growth in operating profit over the past five years, at an annualised rate of 18.27%, this growth is considered poor relative to industry standards and market expectations. The consistency of earnings and operational stability remain concerns, especially given the recent negative quarterly results.

Valuation Considerations

The stock is currently classified as expensive based on valuation metrics. It trades at a Price to Book Value of 4.4, which is high compared to its historical averages and peer group valuations. Despite this, the stock is trading at a discount relative to some peers’ historical valuations, indicating some valuation complexity. The company’s Return on Equity (ROE) stands at 11.8%, which is modest but insufficient to justify the elevated valuation multiple. Investors should be wary of paying a premium for a stock with deteriorating fundamentals.

Financial Trend Analysis

The financial trend for Shree Ganesh Remedies Ltd is very negative. The latest data as of 15 February 2026 shows a significant decline in key financial metrics. Net sales for the latest quarter have fallen by 21.96%, while profit after tax (PAT) has dropped by 43.0%. The company has reported negative results for four consecutive quarters, signalling persistent operational challenges. Additionally, interest expenses have surged by 49.44% over the past nine months, increasing financial strain. These trends highlight deteriorating profitability and cash flow pressures, which weigh heavily on the stock’s outlook.

Technical Outlook

From a technical perspective, the stock is rated as mildly bearish. Despite some short-term positive price movements—such as a 2.31% gain on the most recent trading day and a 22.35% rise over the past month—the stock has underperformed over longer periods. Notably, it has delivered a negative return of 33.44% over the past year, while the broader BSE500 index has generated positive returns of 11.06% during the same timeframe. This divergence suggests weak investor sentiment and technical resistance levels that may be difficult to overcome in the near term.

Stock Performance and Market Position

As of 15 February 2026, Shree Ganesh Remedies Ltd remains a microcap company within the Pharmaceuticals & Biotechnology sector. Its market capitalisation is relatively small, which can contribute to higher volatility and liquidity risks. The stock’s recent performance shows mixed short-term gains but a clear long-term downtrend. The company’s underperformance relative to the market and sector peers is a critical factor in the current rating.

Institutional interest appears limited, with domestic mutual funds holding no stake in the company. This absence of institutional backing may reflect concerns about the company’s valuation, financial health, or growth prospects. Institutional investors typically conduct thorough due diligence, so their lack of participation is a noteworthy signal for retail investors.

Implications for Investors

The Strong Sell rating suggests that investors should exercise caution with Shree Ganesh Remedies Ltd. The combination of weak financial trends, expensive valuation, average quality, and bearish technical signals indicates elevated risk. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector might consider alternative stocks with stronger fundamentals and more favourable valuations.

For existing shareholders, the current rating advises careful monitoring of quarterly results and market developments. Given the company’s recent negative earnings trajectory and rising interest costs, the risk of further downside remains significant. Prospective investors should weigh these factors carefully before initiating positions.

Summary of Key Metrics as of 15 February 2026

Shree Ganesh Remedies Ltd’s Mojo Score currently stands at 26.0, reflecting the Strong Sell grade. This is a decline of 5 points from the previous score of 31 recorded before 12 January 2026. The stock’s recent returns show a mixed picture: a 2.31% gain on the last trading day, 12.65% over the past week, and 22.35% over the last month. However, the six-month return is a mere 0.87%, and the year-to-date return is 13.34%. Most notably, the stock has delivered a negative 33.44% return over the past year, underscoring its underperformance relative to the broader market.

The company’s operating profit growth rate of 18.27% over five years is modest but insufficient to offset recent declines in sales and profitability. The quarterly net sales of ₹21.11 crores have fallen by 21.96%, while quarterly PAT of ₹3.09 crores has declined by 43.0%. Interest expenses have increased to ₹2.69 crores over nine months, growing by 49.44%, which adds to financial pressure.

Conclusion

Shree Ganesh Remedies Ltd’s current Strong Sell rating by MarketsMOJO reflects a comprehensive assessment of its financial health, valuation, quality, and technical outlook as of 15 February 2026. The company faces significant headwinds, including declining sales, shrinking profits, rising interest costs, and a valuation that does not align with its deteriorating fundamentals. Investors should approach this stock with caution and consider the risks carefully in the context of their portfolios and investment objectives.

While short-term price movements have shown some gains, the longer-term trends and financial metrics suggest that the stock is not favourably positioned for growth or stability at present. Monitoring future quarterly results and sector developments will be essential for reassessing the stock’s outlook.

Unlock special upgrade rates for a limited period. Start Saving Now →